Related Experiment Video
Updated: Mar 22, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
21.2K
Single-centre study reports a 84% five-year overall survival rate for paediatric solid tumours
Eero Teppo1, Jarkko Penttinen2, Outi Myöhänen1
1Tampere Center for Child Health Research, University of Tampere and Tampere University Hospital, Tampere, Finland.
Acta Paediatrica (Oslo, Norway : 1992)
|April 10, 2016
Summary
This study on paediatric solid tumours in Finland found survival rates comparable to international standards. Advanced tumour stage at diagnosis was linked to poorer outcomes for children with cancer.
Area of Science:
- Paediatric Oncology
- Clinical Epidemiology
Background:
- Tertiary referral centres play a crucial role in managing childhood malignancies.
- Understanding the characteristics and outcomes of paediatric solid tumours is essential for improving treatment protocols.
Purpose of the Study:
- To investigate the characteristics and treatment outcomes of paediatric patients with solid tumours at Tampere University Hospital.
- To analyze survival rates, common tumour types, and prognostic factors in childhood malignancies.
Main Methods:
- Retrospective cohort study utilizing hospital medical records.
- Data collection included diagnosis, age, sex, tumour characteristics, survival, and recurrence.
- Statistical analysis employed Kaplan-Meier method, non-parametric/parametric tests, and Cox regression modelling.
Main Results:
- 424 paediatric patients with solid tumours were analyzed between 1987 and 2015.
- Central nervous system (CNS) tumours were most frequent (38%), followed by lymphomas (19%).
- The five-year overall survival rate was 84%; advanced tumour stage predicted a poor prognosis.
Conclusions:
- Treatment results are comparable to previously published data.
- A robust local database facilitates effective follow-up of childhood cancer treatment quality.
More Related Videos
Related Concept Videos
02:56Treatment Resistent Cancers
1.5K
1.5K
01:21Cancer Survival Analysis
820
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
820
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
368
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
368
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
441
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
441
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
317
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
317